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Acute stroke often causes immobility, which predisposes 
to deep vein thrombosis and pulmonary embolism and 
these can be fatal or disabling. Low-dose subcutaneous 
anticoagulation with heparins and heparinoids reduces 
the risk of venous thromboembolism, but the beneﬁ t is 
oﬀ set by haemorrhagic complications.1 Even targeting 
anticoagulation to patients at high risk of venous 
thromboembolism and low risk of bleeding does not 
add value because patients at high risk of venous 
thromboembolism (eg, increased severity of stroke) are 
also at high risk of bleeding.2,3 Application of graduated 
compression stockings to the legs is a physical method 
for the prevention of deep vein thrombosis in patients 
undergoing surgery, but it was ineﬀ ective in immobile 
patients with acute stroke in the CLOTS (Clots in Legs 
Or sTockings after Stroke) trials 1 and 2.4,5
Intermittent pneumatic compression (IPC) is another 
physical method for the prevention of deep vein 
thrombosis in patients undergoing surgery. In 2013, 
according to the results of the CLOTS 3 trial, IPC, through 
U-shaped or J-shaped association between outcome of 
acute stroke (deﬁ ned as death or dependency) and on-
treatment blood pressure change—ie, large decreases or 
increases in blood pressure were associated with worse 
outcomes of acute stroke, although cognitive outcomes 
were not assessed.9 In fact, in rare cases or very small trials 
of acute stroke caused by large vessel stenosis, in which 
acute cognitive deﬁ cits are due to regional hypoperfusion 
beyond the infarct, temporary blood pressure elevation 
(with ﬂ uids or pressors) has resulted in improvement in 
cognitive function.10–12 Such cases of large vessel stenosis 
might represent the low end of the J-shaped association—
ie, patients who have a poor outcome with a reduction in 
blood pressure after acute stroke. 
The absence of an identiﬁ ed link between blood 
pressure and cognition in the SPS3 trial has several 
possible explanations. The intervention might not have 
aﬀ ected cognition because there was no signiﬁ cant 
reduction in subsequent stroke. Alternatively, the 
intervention might have been started too late—it might 
be necessary to treat blood pressure before clinically 
signiﬁ cant small vessel disease (before stroke) to prevent 
cognitive decline. Or, it might be too soon (ie, the follow-
up too short) for eﬀ ects on cognition to be identiﬁ ed. 
Neuroprotective eﬀ ects of blood pressure lowering on 
cognitive function, especially in the context of small 
vessel disease, might only be realised many years from 
the start of the intervention. Finally, a J-shaped or 
U-shaped association between blood pressure change 
and cognition might be identiﬁ ed by additional analyses, 
although such associations are more likely to be identiﬁ ed 
after acute strokes caused by large vessel stenosis than 
after acute lacunar strokes (as investigated in SPS3). So, 
despite the negative results of this study, investigators 
should continue to measure cognitive outcomes of 
stroke, and continue to investigate positive long-term 
eﬀ ects of lowering blood pressure, preferably before, but 
also after lacunar stroke. 
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thigh-length sleeves worn on both legs for 30 days and 
nights, was also eﬀ ective in immobile patients with 
acute stroke.6 In The Lancet Neurology, the CLOTS Trials 
Collaboration now reports the results of a prespeciﬁ ed 
follow-up analysis of important secondary outcomes of 
CLOTS 3.7 
In CLOTS 3, allocation to IPC was associated with a 
reduction in the primary outcome of proximal deep 
vein thrombosis within 30 days of randomisation by a 
third compared with no IPC (8·5% vs 12·1%; risk ratio 
[RR] 0·68, 95% CI 0·54–0·85) and a reduction in the 
important secondary outcome of symptomatic deep vein 
thrombosis by a quarter (4·6% vs 6·3%; 0·73, 0·53–0·99).6 
Also, mortality was signiﬁ cantly lower at 6 months after 
randomisation in patients in the IPC group than in the 
no IPC group. Although the proportion of patients who 
had died at the 6 month follow-up was not signiﬁ cantly 
diﬀ erent between the treatment groups (IPC 23·2% vs 
no IPC 25·8%; p=0·12), the probability of death up to 
6 months after randomisation was signiﬁ cantly lower in 
the IPC group according to the results of the Cox model 
survival analysis (hazard ratio 0·86, 95% CI 0·74–0·99; 
p=0·042).6 This apparent discrepancy in the mortality has 
confused some readers. However, the survival analysis is 
the key analysis because it is more sensitive to a small, yet 
real, treatment eﬀ ect of IPC. For example, if all patients 
in CLOTS 3 are followed up for the next 50 years, the 
proportion of patients in each group who will have died 
will be 100%, suggesting that there is no diﬀ erence in 
mortality between the treatment groups. Yet, according 
to the results of a survival analysis there will be a diﬀ erence 
in the time to death.
After the publication of the primary results of CLOTS 3, 
IPC has been widely implemented in stroke units because 
clinicians, for the ﬁ rst time, have felt conﬁ dent that they 
now have a safe strategy for the prevention of deep vein 
thrombosis after stroke. But does a reduction in deep 
vein thrombosis by a third and in death by a seventh with 
IPC translate into an improvement in other outcomes 
that arguably matter more to immobile patients with 
stroke and their families (ie, long-term disability, living 
circumstances, and quality of life) and more to hospital 
managers (ie, hospital costs)?
Although the CLOTS 3 was not powered to reliably 
identify or exclude diﬀ erences in these secondary 
outcomes, the main clinical ﬁ ndings from the new 
secondary analyses are that IPC use reduces the risk of 
deep vein thrombosis and improves survival, but does 
not improve disability, likelihood of living at home, 
quality of life, or quality-adjusted life days over the 
ﬁ rst 6 months compared with no IPC use. A caveat to 
these results is that the utility values used to estimate 
quality of life and quality-adjusted life days were based 
on the preferences of stroke-free individuals in the UK 
and might, or might not, reﬂ ect the views of patients 
with stroke or their carers. The main economic results 
are that IPC use is not expensive (£64·10 per patient or 
£5·48 per day of treatment), but that it increases overall 
hospital costs by improving survival and thus increasing 
the duration of hospital stay. 
In the IPC group, case fatality was reduced by 3% at 
6 months compared with no IPC (23% vs 26%; p=0·12).7 
It is presumed, but not reported, that the reduction in 
case fatality with IPC was due to a reduction in the risk of 
fatal pulmonary embolism. The survival advantage with 
IPC was oﬀ set, however, by a 4% absolute increase in 
patients severely disabled (Oxford Handicap Score 5) at 
6 months compared with no IPC (22% vs 18%; p=0·013). 
This ﬁ nding might be due to chance because it is the 
result of a post-hoc exploratory analysis. However, it 
could also be real because the patients who are likely 
to develop a deep vein thrombosis, and have their life 
saved by IPC, are also likely to be disabled should they 
survive; stroke severity is a predictor of both deep vein 
thrombosis and severe disability.3,8 If so, the situation is 
similar to that of decompressive hemicraniectomy for 
malignant middle-cerebral-artery infarction in patients 
older than 60 years, whereby early hemicraniectomy 
signiﬁ cantly increases the probability of survival but 
most survivors have substantial disability.9 Survival with 
substantial disability instead of death is an outcome that 
might be acceptable to some patients and carers whereas 
it might not be acceptable to others.
The CLOTS Trials Collaboration is to be congratulated 
for completing the long-term follow-up of enrolled 
patients beyond that required for the primary 
outcome. The results of this secondary analysis provide 
important contextual information that tempers the 
enthusiastic conclusions drawn from the results of 
the primary eﬃ  cacy analysis and enrich the evidence 
base for deciding whether to use or not use IPC. On the 
one hand, IPC use is an aﬀ ordable intervention that 
prevents deep vein thrombosis and saves lives in some 
immobile patients with stroke who are hospitalised in 
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the UK. On the other hand, IPC use does not improve 
overall functional outcome or quality-adjusted survival. 
Whether these ﬁ ndings are generalisable to immobile 
patients with acute stroke who are managed with IPC 
outside the UK is uncertain and awaits further study.
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What is the course of Huntington’s disease? 
Studying the course of Huntington’s disease oﬀ ers the rare 
opportunity to examine changes in a neurodegenerative 
process, years or even decades before unequivocal 
symptoms enable the clinical diagnosis to be made. 
Studies such as PREDICT-HD, an analysis1 from which is 
reported by Jane  Paulsen and colleagues in The Lancet 
Neurology, and TRACK-HD2 describe early predictors such 
as imaging data and cognitive, behavioural, motor, and 
quantitative motor measures that have prognostic value.
The description of neuropsychiatric changes many 
years before the occurrence of motor symptoms in 
Huntington’s disease is not new.3 Now, however, a 
very precise quantiﬁ cation of these changes, occurring 
12–15 years before diagnosis, is possible.4 Paulsen 
and colleagues followed up 1078 individuals with the 
Huntington’s disease gene mutation for a mean of 
5 years (up to a maximum of 12 years), and showed that 
the best predictors of diagnosis beyond that provided 
by age and mutation repeat length in the top three 
phenotypic domains were total motor score, putamen 
volume, and Stroop word test. 
Advances in the understanding of the pathophysiology 
of the disease from research in animal models have led 
to various potential therapeutic approaches.5 For some 
of these approaches, the ﬁ rst steps from preclinical to 
clinical research have been taken.
Such developments raise several questions. What is the 
disease onset for Huntington’s disease? If a treatment 
becomes available in the future, when in the course 
of the disease should we start to use it? Currently, the 
diagnosis of manifest Huntington’s disease is based 
on the presence of unequivocal motor signs (99% or 
100% conﬁ dence, ie a diagnostic conﬁ dence level [DCL] 
of 4, on the Uniﬁ ed Huntington’s Disease Rating Scale 
[UHDRS]).6 How can we deﬁ ne a 99–100% conﬁ dence 
in diagnosis in more detail? Is there a special cutoﬀ  value 
in the motor score of the UHDRS for the establishment 
of the diagnosis? TRACK-HD2 used the strict inclusion 
criterion of 5 or fewer points in this scale for inclusion of 
premanifest mutation carriers. After 1 year, a signiﬁ cant 
increase in this measure was noted, without any further 
increase in the subsequent years.2 PREDICT-HD used the 
classic DCL of 4 as a criterion, and participants who were 
diagnosed with Huntington’s disease had a mean UHDRS 
total motor score of 22 (SD 9) at the time of diagnosis.1 
More interestingly, in PREDICT-HD,1 participants without 
the mutation were shown to have an age-dependent 
increase in the UHDRS total motor score, with a 99th 
